Research advance of population pharmacokinetics of imipenem-cilastatin in special status populations / 中国药房
China Pharmacy
; (12): 1141-1146, 2022.
Article
in Zh
| WPRIM
| ID: wpr-923766
Responsible library:
WPRO
ABSTRACT
Imipenem-cilastatin is a broad-spectrum carbapenem antibiotic drug that has been widely used in clinical practice , but there is a lack of guidelines and expert consensus on the development of individualized regimens for special status populations [e.g. continuous renal replacement therapy (CRRT)patients,extracorporeal membrane oxygenation (ECMO)patients, critically ill burn patients ,neonates and children]. In this paper ,by searching population pharmacokinetics research of imipenem- cilastatin in special status populations ,it is recommended that imipenem-cilastatin is given 1 to 3 g/d for CRRT patients ;500 mg to 1 g,q6 h for burn patients ;750 mg to 1 g,q6 h for ECMO patients ;20 mg/kg or 25 mg/kg,q8 h for neonates ;and 25 mg/kg,q6 h for children.
Full text:
1
Index:
WPRIM
Type of study:
Guideline
Language:
Zh
Journal:
China Pharmacy
Year:
2022
Type:
Article